Luc Mongeau Sells 135,231 Shares of Canopy Growth (NASDAQ:CGC) Stock

Canopy Growth Corporation (NASDAQ:CGCGet Free Report) CEO Luc Mongeau sold 135,231 shares of the stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $0.97, for a total value of $131,174.07. Following the sale, the chief executive officer owned 1,723,913 shares of the company’s stock, valued at approximately $1,672,195.61. The trade was a 7.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Canopy Growth Stock Down 1.1%

Shares of NASDAQ:CGC opened at $0.95 on Wednesday. The company has a market capitalization of $382.38 million, a price-to-earnings ratio of -1.60 and a beta of 0.77. The company has a debt-to-equity ratio of 0.31, a current ratio of 3.34 and a quick ratio of 2.64. The business’s 50-day moving average is $1.07 and its 200-day moving average is $1.12. Canopy Growth Corporation has a 1 year low of $0.84 and a 1 year high of $2.38.

Canopy Growth (NASDAQ:CGCGet Free Report) last announced its earnings results on Monday, June 15th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.11). Canopy Growth had a negative net margin of 75.27% and a negative return on equity of 26.95%. The business had revenue of $51.22 million for the quarter, compared to the consensus estimate of $53.43 million. Equities research analysts predict that Canopy Growth Corporation will post -0.11 earnings per share for the current year.

Key Stories Impacting Canopy Growth

Here are the key news stories impacting Canopy Growth this week:

Institutional Investors Weigh In On Canopy Growth

Hedge funds have recently added to or reduced their stakes in the company. Jones Financial Companies Lllp raised its position in shares of Canopy Growth by 10,308.3% during the first quarter. Jones Financial Companies Lllp now owns 969,533 shares of the company’s stock worth $882,000 after purchasing an additional 960,218 shares during the period. Goldman Sachs Group Inc. grew its position in Canopy Growth by 64.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 330,278 shares of the company’s stock valued at $301,000 after purchasing an additional 129,620 shares during the period. Murchinson Ltd. bought a new stake in Canopy Growth during the 2nd quarter valued at $183,000. Boothbay Fund Management LLC bought a new stake in Canopy Growth during the 2nd quarter valued at $30,000. Finally, Tidal Investments LLC raised its holdings in Canopy Growth by 31.5% during the second quarter. Tidal Investments LLC now owns 5,033,793 shares of the company’s stock worth $6,141,000 after buying an additional 1,204,530 shares during the last quarter. Institutional investors and hedge funds own 3.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on CGC. ATB Cormark Capital Markets upgraded shares of Canopy Growth from a “strong sell” rating to a “moderate buy” rating in a research note on Tuesday, March 17th. Wall Street Zen lowered shares of Canopy Growth from a “hold” rating to a “sell” rating in a research note on Sunday, March 29th. Weiss Ratings cut shares of Canopy Growth from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 15th. Finally, Canaccord Genuity Group initiated coverage on shares of Canopy Growth in a research note on Friday, March 27th. They issued a “buy” rating for the company. Two research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

View Our Latest Stock Analysis on Canopy Growth

About Canopy Growth

(Get Free Report)

Canopy Growth Corporation is a leading Canadian cannabis company engaged in the production, distribution and sale of both medical and recreational cannabis products. Headquartered in Smiths Falls, Ontario, the company cultivates a diversified portfolio of offerings that includes dried flower, pre-rolled joints, oils, softgel capsules and edibles. Canopy Growth also markets derivative products such as beverages and wellness formulations under a range of brands, aiming to serve both patient and adult-use markets.

The company operates through multiple subsidiaries, including Tweed Inc, Spectrum Therapeutics and Tokyo Smoke, each targeting distinct consumer segments.

Featured Stories

Insider Buying and Selling by Quarter for Canopy Growth (NASDAQ:CGC)

Receive News & Ratings for Canopy Growth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Canopy Growth and related companies with MarketBeat.com's FREE daily email newsletter.